Missing values [Study Per­for­mance]

posted by Helmut Homepage – Vienna, Austria, 2008-07-30 19:14 (6126 d 07:50 ago) – Posting: # 2109
Views: 16,878

Dear Martin,

I’m with you in the definition of data sets (especially PKAS(b) etc. etc.)…
The important point is an a-priori strategy, which has to be adapted according to the PK characteristics of the drug, etc.

❝ regarding the importance of FADS and PADS: the FADS should reflect the clinical situation in practice better than the rather artificial PADS and is according to my point of view more important.


Yes, but phase I trials never reflect the clinical situation.
IMPs in a BE study are not labeled for sole use in healthy male Caucasian* subjects, preferably non-smokers of a BMI [19-27] fasting four hours after administration together with 150 mL non-carbonated water of ambient temperature avoiding methyl-xanthine containing food and beverages as well as grapefruit juice, charcoal broiled meat and broccoli during the study (did I forget something?). :cool:
A properly designed BE study should be powered to be able to detect differences between formulations in the smallest possible number of subjects – which we hope to attain by a high degree of standardization. This has nothing in common with the clinical situation.

❝ […] thanks for the very interesting discussion


Same to you!



Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,671 registered users;
143 visitors (0 registered, 143 guests [including 9 identified bots]).
Forum time: 03:05 CEST (Europe/Vienna)

Freedom is always and exclusively
freedom for the one
who thinks differently.    Rosa Luxemburg

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5